Company news

Amneal Pharmaceuticals, Inc. news in 2023

Amneal Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Amneal Announces Move to Nasdaq

December 14, 2023

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

December 6, 2023

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

November 30, 2023

Amneal Reports Third Quarter 2023 Financial Results

November 6, 2023

Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance

October 22, 2023

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

October 11, 2023

Amneal to Report Third Quarter 2023 Results on November 7, 2023

October 4, 2023

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

September 5, 2023

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

September 5, 2023

Amneal Receives First Product Approval in China

September 5, 2023

Amneal Reports Second Quarter 2023 Financial Results

August 3, 2023

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

July 25, 2023

Amneal to Report Second Quarter 2023 Results on August 4, 2023

July 5, 2023

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

July 2, 2023

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

June 14, 2023

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable

June 13, 2023

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

May 15, 2023

Amneal Reports First Quarter 2023 Financial Results

May 4, 2023

Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance

April 16, 2023

Amneal to Report First Quarter 2023 Results on May 5, 2023

April 11, 2023

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

March 1, 2023

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

March 1, 2023

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

January 30, 2023

Amneal Announces Strategic European Partnership with Orion Corporation

January 3, 2023

Calls in 2023

Decks in 2023